|
|
Article: FDA To Cardiome: More Data Needed To Clear Oxypurinol.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Cardiome Pharma Corp.'s stock held steady Thursday after the company reported that the FDA wants additional clinical and manufacturing data before it will approve oxypurinol for gout.
The company's stock (OTC BB:COMRF) fell 8 cents Thursday to close at $5.32.
Bob Rieder, president and CEO of Vancouver, British Columbia-based Cardiome, said the gout opportunity is "very small," adding that the company's main focus is on its cardiovascular drug development programs.
Nevertheless, the FDA issued an approvable letter on the oxypurinol (Oxyprim) application, which was submitted in December under accelerated approval ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cardiome Expanding Pipeline Through Artesian Acquisition.
BIOWORLD Today;
November 3, 2009 ;
700+ words
... ... Doug Janzen, Cardiome's chief financial officer, told BioWorld Today. He added that ... put money into Cardiome" by way of a ... oxypurinol, the Cardiome drug that recently ... trial. (See BioWorld Today, Aug. 16, 2005 ...
|
|